Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash & Equivalents for 3 consecutive years, with $124.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 18.6% to $124.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124.2 million through Dec 2025, down 18.6% year-over-year, with the annual reading at $124.2 million for FY2025, 18.6% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $124.2 million at Inhibrx Biosciences, down from $153.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $277.9 million in Q4 2023, with the low at $124.2 million in Q4 2025.
  • Average Cash & Equivalents over 3 years is $191.8 million, with a median of $191.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents plummeted 45.09% in 2024, then fell 17.78% in 2025.
  • Over 3 years, Cash & Equivalents stood at $277.9 million in 2023, then crashed by 45.09% to $152.6 million in 2024, then decreased by 18.6% to $124.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $124.2 million, $153.1 million, and $186.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.